Incyte Corporation vs Ralph Lauren Corp — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Ralph Lauren Corp trades at $397.8 (market cap $23.70B). The key difference: Incyte Corporation and Ralph Lauren Corp are close in size by market cap, and Ralph Lauren Corp pays a 0.94% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RL | |
|---|---|---|
Market Cap | $24.54B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $414.25 |
52-Week Low | $81.61 | $285.35 |
Enterprise Value | $20.04B | $24.76B |
Dividend Yield | — | 0.94% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →